Ocugen (OCGN) EBITDA Margin (2014 - 2026)
Ocugen's (OCGN) quarterly EBITDA Margin came in at 1163.67% in Q1 2026, down 18453.0% YoY from N/an in Q1 2025, and down 113.21% on a QoQ basis from 8805.7% in Q4 2025.
Ocugen (OCGN) EBITDA Margin (2014 - 2026) Analysis & Trends
Ocugen (OCGN) has 7 years of EBITDA Margin data on file, last reported at 1163.67% in Q1 2026.
- Quarterly EBITDA Margin fell 18453.0% year-over-year to 1163.67% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1483.85% (down 22242.0% YoY) and the FY2025 annual result came in at 1425.7%, down 7534.0% from the prior year.
- EBITDA Margin fell to 1163.67% in Q1 2026, from 8805.7% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 8805.7% in Q4 2025 to a low of 5388.41% in Q3 2022.
- A 5-year average of 1539.43% and a median of 1204.73% in 2024 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2023 — EBITDA Margin tumbled 149809 bps — and 2025, when it surged 1061722 bps.
- Tracing OCGN's EBITDA Margin over 5 years: stood at 2657.0% in 2022, then surged by 69 bps to 817.96% in 2023, then plunged by 121 bps to 1811.52% in 2024, then soared by 586 bps to 8805.7% in 2025, then sank by 113 bps to 1163.67% in 2026.
- The last three EBITDA Margin figures came in at 1163.67% (Q1 2026), 8805.7% (Q4 2025), and 1005.99% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Ocugen | 457.71 Mn | 357.61 Mn | - | -1,105.11% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,105.11% |
| Mar 31, 2026 | -1,163.67% |
| Dec 31, 2025 | 8,805.70% |
| Sep 30, 2025 | -1,005.99% |
| Jun 30, 2025 | -1,004.73% |
| Mar 31, 2025 | -979.14% |
| Dec 31, 2024 | -1,811.52% |
| Sep 30, 2024 | -1,166.55% |
| Jun 30, 2024 | -1,353.99% |
| Mar 31, 2024 | -1,204.73% |
| Dec 31, 2023 | -817.96% |
| Sep 30, 2023 | -336.06% |
| Jun 30, 2023 | -4,853.61% |
| Mar 31, 2023 | -4,071.11% |
| Dec 31, 2022 | -2,657.00% |
| Sep 30, 2022 | -5,388.41% |
| Jun 30, 2022 | -3,355.52% |
| Mar 31, 2022 | -3,806.00% |
| Jun 30, 2020 | -7,827.91% |
| Sep 30, 2014 | -4.98% |